Current Report Filing (8-k)
May 15 2017 - 04:59PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): May 15, 2017
Commission File Number: 001-37544
AmpliPhi
Biosciences Corporation
(Exact name of Registrant as specified
in its charter)
Washington
|
91-1549568
|
(State or other jurisdiction of incorporation or
organization)
|
(IRS Employer Identification No.)
|
3579 Valley Centre Drive, Suite 100
San Diego, California 92130
(Address of principal executive offices)
(858) 829-0829
(Registrant’s Telephone number)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
ý
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
ý
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2017, we announced our financial
results for the quarter ended March 31, 2017 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 and the
attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02
and the attached exhibit shall not be incorporated by reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibits.
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by AmpliPhi Biosciences Corporation on May 15, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 15, 2017
|
AmpliPhi Biosciences Corporation
|
|
|
|
|
|
By:
|
/s/ Steve R. Martin
|
|
|
Name:
|
Steve R. Martin
|
|
|
Title:
|
Chief Financial Officer
|
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release issued by AmpliPhi Biosciences Corporation on May 15, 2017
|
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Mar 2023 to Mar 2024